Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Comment by mumfordsenon Jun 23, 2018 12:59am
137 Views
Post# 28217511

RE:Here's Why This Is Such a Great Buy Right NOW!!!

RE:Here's Why This Is Such a Great Buy Right NOW!!!
Hotoffthepress wrote: 1. Trial completion news any day (end of June)
2. Trial results news early Q3 (July?)
3. Trial just needs to show safety, tolerabiity and pharmacodynamics.  Blood levels need to be comparable to injection (does not need to show Efficacy)
4. Safety and tolerability already demonstrated in a previous trial
5. Company is "partnership discussions" in Europe, India, China and N. America for over 18 months
6.  This may be our final trial?? (need confirmation) prior to FDA submission
7. We own the rights to Bertilimumba, going into Phase III in early 2019 with Immune
8. Immune owes us several million dollars (milestones) as soon as they start Phase III
9. Bertilimumab is Immunes lead drug so they must press for Phase III
10. We are expecting PK/PD data on Beriliumamb in Q3
11. Immune meeting FDA in Q3 to discuss Phase III so expect a PR
12. We have an AGM meeting next week in Vancouver on June 27th at 10:00am


<< Previous
Bullboard Posts
Next >>